Bafiertam vs Diroximel fumarate

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Sclerosis

Shared mechanism: Nrf2 pathway (fumaric acid ester) · full Multiple Sclerosis pipeline

Bafiertam

Marketed by Cycle Pharmaceuticals Ltd.

Approved in Multiple Sclerosissmall molecule (fumarate)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Diroximel fumarate · Vumerity

Marketed by Biogen and partners

Approved in Multiple Sclerosissmall molecule (fumarate prodrug)
Weak signal

NCT05083923 · Phase 3 · completed

The study was a single-group, open-label trial with 136 participants enrolled and no placebo or active comparator. Its primary outcomes were safety measures rather than a comparative clinical efficacy endpoint, so there was no formal primary treatment comparison to meet or miss; the reported safety findings are descriptive only.

Next expected readout: July 2034 · NCT07483632 (registry estimate)

Reported efficacy

Number of Days With Any Individual Gastrointestinal Symptom and Impact Scale (IGISIS) Individual Symptom Intensity Score ≥2 Relative to Exposure Days in Parts A and B (End of treatment (up to Week 6) for both Parts A and B): Primary GI symptom days: mean 1.5 (SD 2.85) with ALKS 8700 vs 2.5 (SD 4.68) with dimethyl fumarate; rate ratio 0.542 (95% CI 0.390-0.754), p=0.0003. (met)

Result source: NCT03093324

Results for Multiple Sclerosis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBafiertamDiroximel fumarate
Annualised relapse rate—Not reported—Trial running · NCT07483632
Free of 3-month confirmed disability progression (%)—Not reported—Trial running · NCT07483632
New or enlarging T2 lesions—Not reported—Trial running · NCT07483632

Annualised relapse rate

Bafiertam
—Not reported
Diroximel fumarate
—Trial running · NCT07483632

Free of 3-month confirmed disability progression (%)

Bafiertam
—Not reported
Diroximel fumarate
—Trial running · NCT07483632

New or enlarging T2 lesions

Bafiertam
—Not reported
Diroximel fumarate
—Trial running · NCT07483632
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Bafiertam: 2 of 4 rows · Diroximel fumarate: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBafiertamDiroximel fumarate
Dropout rate
—a
NCT04570670 · Phase 1
9.6%Cohort 1: Japanese Participantsb
NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 5 more results
20%Cohort 2: Chinese Participants
NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
21.1%De Novo
NCT02634307 · Phase 3 · monotherapy
29.7%Rollover: ALKS 8700
NCT02634307 · Phase 3 · monotherapy
27.1%Rollover: DMF
NCT02634307 · Phase 3 · monotherapy
3.5%
NCT03093324 · Phase 3 · monotherapy
Discontinued due to AEs
—a
NCT04570670 · Phase 1
3.8%Cohort 1: Japanese Participantsb
NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 5 more results
0%Cohort 2: Chinese Participants
NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
8.4%De Novo
NCT02634307 · Phase 3 · monotherapy
10%Rollover: ALKS 8700
NCT02634307 · Phase 3 · monotherapy
6.2%Rollover: DMF
NCT02634307 · Phase 3 · monotherapy
1.6%
NCT03093324 · Phase 3 · monotherapy
Serious AEs
0%a
NCT04570670 · Phase 1
11.5%Cohort 1: Japanese Participantsb
NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 5 more results
12%Cohort 2: Chinese Participants
NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
11.6%De Novo
NCT02634307 · Phase 3 · monotherapy
12.1%Rollover: ALKS 8700
NCT02634307 · Phase 3 · monotherapy
11.1%Rollover: DMF
NCT02634307 · Phase 3 · monotherapy
1.6%
NCT03093324 · Phase 3 · monotherapy
Most frequent reported AEs
a
flushing 60%
abdominal pain 2%
anxiety 2%
NCT04570670 · Phase 1
b
diarrhoea 36.5%
flushing 32.7%
nasopharyngitis 21.2%
NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 5 more results
upper respiratory tract infection 36%
flushing 18%
lymphocyte count decreased 16%
NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
flushing 38.1%
multiple sclerosis relapse 15.7%
nasopharyngitis 14.5%
NCT02634307 · Phase 3 · monotherapy
multiple sclerosis relapse 19.7%
upper respiratory tract infection 17.6%
lymphopenia 14.6%
NCT02634307 · Phase 3 · monotherapy
multiple sclerosis relapse 19.6%
lymphopenia 16.9%
upper respiratory tract infection 15.6%
NCT02634307 · Phase 3 · monotherapy
flushing 32.8%
diarrhoea 15.4%
nausea 14.6%
NCT03093324 · Phase 3 · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 4 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Diroximel fumarate

Annualized Relapse 0.14 per year @ 96wk
event rate · per year
No placebo or comparator arm
NCT02634307 · Phase 3 · monotherapy
show 2 more results
0.11 per year @ 96wk
NCT02634307 · Phase 3 · monotherapy
0.13 per year @ 96wk
NCT02634307 · Phase 3 · monotherapy
Relapse 17.66% (n=593) @ 96wk
responder rate · % of participants
No placebo or comparator arm
NCT02634307 · Phase 3 · monotherapy
show 2 more results
16.66% (n=239) @ 96wk
NCT02634307 · Phase 3 · monotherapy
18.3% (n=225) @ 96wk
NCT02634307 · Phase 3 · monotherapy
EDSS -0.01 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT02634307 · Phase 3 · monotherapy
show 23 more results
-0.03 score @ 12wk
NCT02634307 · Phase 3 · monotherapy
0.05 score @ 12wk
NCT02634307 · Phase 3 · monotherapy
0 score @ 24wk
NCT02634307 · Phase 3 · monotherapy
-0.02 score @ 24wk
NCT02634307 · Phase 3 · monotherapy
-0.01 score @ 24wk
NCT02634307 · Phase 3 · monotherapy
0.01 score @ 36wk
NCT02634307 · Phase 3 · monotherapy
-0.01 score @ 36wk
NCT02634307 · Phase 3 · monotherapy
-0.03 score @ 36wk
NCT02634307 · Phase 3 · monotherapy
0.03 score @ 48wk
NCT02634307 · Phase 3 · monotherapy
-0.01 score @ 48wk
NCT02634307 · Phase 3 · monotherapy
0 score @ 48wk
NCT02634307 · Phase 3 · monotherapy
0.04 score @ 60wk
NCT02634307 · Phase 3 · monotherapy
-0.02 score @ 60wk
NCT02634307 · Phase 3 · monotherapy
-0.02 score @ 60wk
NCT02634307 · Phase 3 · monotherapy
0.05 score @ 72wk
NCT02634307 · Phase 3 · monotherapy
-0.04 score @ 72wk
NCT02634307 · Phase 3 · monotherapy
0.08 score @ 72wk
NCT02634307 · Phase 3 · monotherapy
0.07 score @ 84wk
NCT02634307 · Phase 3 · monotherapy
-0.03 score @ 84wk
NCT02634307 · Phase 3 · monotherapy
-0.02 score @ 84wk
NCT02634307 · Phase 3 · monotherapy
0.07 score @ 96wk
NCT02634307 · Phase 3 · monotherapy
-0.01 score @ 96wk
NCT02634307 · Phase 3 · monotherapy
0.03 score @ 96wk
NCT02634307 · Phase 3 · monotherapy
T25FW -0.05 seconds @ 12wk
absolute change · seconds
No placebo or comparator arm
NCT02634307 · Phase 3 · monotherapy
show 23 more results
0 seconds @ 12wk
NCT02634307 · Phase 3 · monotherapy
0 seconds @ 12wk
NCT02634307 · Phase 3 · monotherapy
0 seconds @ 24wk
NCT02634307 · Phase 3 · monotherapy
-0.05 seconds @ 24wk
NCT02634307 · Phase 3 · monotherapy
0 seconds @ 24wk
NCT02634307 · Phase 3 · monotherapy
-0.05 seconds @ 36wk
NCT02634307 · Phase 3 · monotherapy
-0.1 seconds @ 36wk
NCT02634307 · Phase 3 · monotherapy
0 seconds @ 36wk
NCT02634307 · Phase 3 · monotherapy
0 seconds @ 48wk
NCT02634307 · Phase 3 · monotherapy
0 seconds @ 48wk
NCT02634307 · Phase 3 · monotherapy
-0.05 seconds @ 48wk
NCT02634307 · Phase 3 · monotherapy
-0.05 seconds @ 60wk
NCT02634307 · Phase 3 · monotherapy
-0.09 seconds @ 60wk
NCT02634307 · Phase 3 · monotherapy
0 seconds @ 60wk
NCT02634307 · Phase 3 · monotherapy
0 seconds @ 72wk
NCT02634307 · Phase 3 · monotherapy
-0.05 seconds @ 72wk
NCT02634307 · Phase 3 · monotherapy
0 seconds @ 72wk
NCT02634307 · Phase 3 · monotherapy
-0.05 seconds @ 84wk
NCT02634307 · Phase 3 · monotherapy
-0.075 seconds @ 84wk
NCT02634307 · Phase 3 · monotherapy
0 seconds @ 84wk
NCT02634307 · Phase 3 · monotherapy
-0.05 seconds @ 96wk
NCT02634307 · Phase 3 · monotherapy
-0.05 seconds @ 96wk
NCT02634307 · Phase 3 · monotherapy
0 seconds @ 96wk
NCT02634307 · Phase 3 · monotherapy
EQ-5D VAS 1 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT02634307 · Phase 3 · monotherapy
show 11 more results
-1.6 score @ 24wk
NCT02634307 · Phase 3 · monotherapy
-1.6 score @ 24wk
NCT02634307 · Phase 3 · monotherapy
0.3 score @ 48wk
NCT02634307 · Phase 3 · monotherapy
-2.8 score @ 48wk
NCT02634307 · Phase 3 · monotherapy
-1.9 score @ 48wk
NCT02634307 · Phase 3 · monotherapy
1.3 score @ 72wk
NCT02634307 · Phase 3 · monotherapy
-2.8 score @ 72wk
NCT02634307 · Phase 3 · monotherapy
-2.1 score @ 72wk
NCT02634307 · Phase 3 · monotherapy
0.6 score @ 96wk
NCT02634307 · Phase 3 · monotherapy
-4.2 score @ 96wk
NCT02634307 · Phase 3 · monotherapy
-3.7 score @ 96wk
NCT02634307 · Phase 3 · monotherapy
EQ-5D Index -0.002 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT02634307 · Phase 3 · monotherapy
show 11 more results
-0.018 score @ 24wk
NCT02634307 · Phase 3 · monotherapy
-0.035 score @ 24wk
NCT02634307 · Phase 3 · monotherapy
-0.006 score @ 48wk
NCT02634307 · Phase 3 · monotherapy
-0.026 score @ 48wk
NCT02634307 · Phase 3 · monotherapy
-0.037 score @ 48wk
NCT02634307 · Phase 3 · monotherapy
-0.01 score @ 72wk
NCT02634307 · Phase 3 · monotherapy
-0.03 score @ 72wk
NCT02634307 · Phase 3 · monotherapy
-0.036 score @ 72wk
NCT02634307 · Phase 3 · monotherapy
-0.009 score @ 96wk
NCT02634307 · Phase 3 · monotherapy
-0.042 score @ 96wk
NCT02634307 · Phase 3 · monotherapy
-0.057 score @ 96wk
NCT02634307 · Phase 3 · monotherapy
Time to Confirmed Disability Progression 8.21 months
time to event · months
No placebo or comparator arm
NCT02634307 · Phase 3 · monotherapy · converted to months from 250 days as posted
show 2 more results
8.36 months*
NCT02634307 · Phase 3 · monotherapy · converted to months from 254.5 days as posted
5.78 months*
NCT02634307 · Phase 3 · monotherapy · converted to months from 176 days as posted
NEDA 24.8% (n=487) @ 96wk
responder rate · % of participants
No placebo or comparator arm
NEDA-3
NCT02634307 · Phase 3 · monotherapy
show 2 more results
34.6% (n=185) @ 96wk
NEDA-3
NCT02634307 · Phase 3 · monotherapy
28.6% (n=185) @ 96wk
NEDA-3
NCT02634307 · Phase 3 · monotherapy
NEDA-4 14.3% (n=487) @ 96wk
responder rate · % of participants
No placebo or comparator arm
NEDA-4
NCT02634307 · Phase 3 · monotherapy
show 2 more results
15.2% (n=185) @ 96wk
NEDA-4
NCT02634307 · Phase 3 · monotherapy
11.9% (n=185) @ 96wk
NEDA-4
NCT02634307 · Phase 3 · monotherapy

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bafiertam's landscape · Diroximel fumarate's landscape